Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Bcl2 inhibitor
DRUG CLASS:
Bcl2 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
venetoclax (380)
paclitaxel (162)
albumin-bound paclitaxel (53)
ABT 263 (16)
APG-2575 (7)
APG-1252 (6)
micellar paclitaxel (3)
APG1244 (2)
BGB-11417 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
AT 101 (1)
S55746 (1)
venetoclax (380)
paclitaxel (162)
albumin-bound paclitaxel (53)
ABT 263 (16)
APG-2575 (7)
APG-1252 (6)
micellar paclitaxel (3)
APG1244 (2)
BGB-11417 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
AT 101 (1)
S55746 (1)
›
Associations
(634)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
PD-L1 expression
Gastric Cancer
PD-L1 expression
Gastric Cancer
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 2wk
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 2wk
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS G12R
Pancreatic Ductal Adenocarcinoma
KRAS G12R
Pancreatic Ductal Adenocarcinoma
paclitaxel + gemcitabine
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
paclitaxel + gemcitabine
Sensitive
:
C3
ASCO-GI 2023 - 2wk
paclitaxel + gemcitabine
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
paclitaxel + gemcitabine
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
BRCA wild-type
Ovarian Cancer
BRCA wild-type
Ovarian Cancer
carboplatin + paclitaxel
Sensitive: C3 – Early Trials
Int J Gynecol Cancer - 3 weeks (New C3)
carboplatin + paclitaxel
Sensitive
:
C3
Int J Gynecol Cancer - 3wk
carboplatin + paclitaxel
Sensitive: C3 – Early Trials
Int J Gynecol Cancer - 3 weeks
carboplatin + paclitaxel
Sensitive
:
C3
Int J Gynecol Cancer - 3 weeks - (New C3)
BCL2 underexpression
Ewing Sarcoma
BCL2 underexpression
Ewing Sarcoma
venetoclax
Sensitive: D – Preclinical
Biochem Pharmacol - 4 weeks (New D)
venetoclax
Sensitive
:
D
Biochem Pharmacol - 4wk
venetoclax
Sensitive: D – Preclinical
Biochem Pharmacol - 4 weeks
venetoclax
Sensitive
:
D
Biochem Pharmacol - 4 weeks - (New D)
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
carboplatin + micellar paclitaxel
Sensitive
:
A1
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
carboplatin + micellar paclitaxel
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
carboplatin + micellar paclitaxel
Sensitive
:
A1
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
carboplatin + micellar paclitaxel
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
venetoclax + rituximab
Sensitive: A1 - Approval
venetoclax + rituximab
Sensitive
:
A1
venetoclax + rituximab
Sensitive: A1 - Approval
venetoclax + rituximab
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
carboplatin + micellar paclitaxel
Sensitive
:
A1
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
carboplatin + micellar paclitaxel
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
carboplatin + albumin-bound paclitaxel
Sensitive: A1 - Approval
carboplatin + albumin-bound paclitaxel
Sensitive
:
A1
carboplatin + albumin-bound paclitaxel
Sensitive: A1 - Approval
carboplatin + albumin-bound paclitaxel
Sensitive
:
A1
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A1 - Approval
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A1
gemcitabine + albumin-bound paclitaxel
Sensitive: A1 - Approval
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
albumin-bound paclitaxel
Sensitive: A1 - Approval
albumin-bound paclitaxel
Sensitive
:
A1
albumin-bound paclitaxel
Sensitive: A1 - Approval
albumin-bound paclitaxel
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
venetoclax + ibrutinib
Sensitive: A1 - Approval
venetoclax + ibrutinib
Sensitive
:
A1
venetoclax + ibrutinib
Sensitive: A1 - Approval
venetoclax + ibrutinib
Sensitive
:
A1
No biomarker
Oral Cancer
No biomarker
Oral Cancer
cisplatin + paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + paclitaxel + 5-fluorouracil
Sensitive
:
A2
cisplatin + paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + paclitaxel + 5-fluorouracil
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
cisplatin + paclitaxel
Sensitive: A2 - Guideline
cisplatin + paclitaxel
Sensitive
:
A2
cisplatin + paclitaxel
Sensitive: A2 - Guideline
cisplatin + paclitaxel
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
No biomarker
Oropharyngeal Cancer
cisplatin + paclitaxel
Sensitive: A2 - Guideline
cisplatin + paclitaxel
Sensitive
:
A2
cisplatin + paclitaxel
Sensitive: A2 - Guideline
cisplatin + paclitaxel
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
No biomarker
Oropharyngeal Cancer
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
No biomarker
Oropharyngeal Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Oropharyngeal Cancer
No biomarker
Oropharyngeal Cancer
cisplatin + paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + paclitaxel + 5-fluorouracil
Sensitive
:
A2
cisplatin + paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + paclitaxel + 5-fluorouracil
Sensitive
:
A2
No biomarker
Nasopharyngeal Carcinoma
No biomarker
Nasopharyngeal Carcinoma
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Cervical Cancer
No biomarker
Cervical Cancer
paclitaxel + topotecan
Sensitive: A2 - Guideline
paclitaxel + topotecan
Sensitive
:
A2
paclitaxel + topotecan
Sensitive: A2 - Guideline
paclitaxel + topotecan
Sensitive
:
A2
IDH2 mutation
Acute Myelogenous Leukemia
IDH2 mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
carboplatin + albumin-bound paclitaxel
Sensitive: A2 - Guideline
carboplatin + albumin-bound paclitaxel
Sensitive
:
A2
carboplatin + albumin-bound paclitaxel
Sensitive: A2 - Guideline
carboplatin + albumin-bound paclitaxel
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login